Use data of all dosed subjects [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2019-09-19 15:16 (432 d 05:17 ago) – Posting: # 20617
Views: 4,170

Hi Elena,

» […] What combined data should be evaluated after stage 2 completion: ONLY for Cmax or for Cmax and AUCt?

Whatever drives the second stage, you have to use all data (Cmax and AUC). Whilst from a statistical perspective there would be no need to assess AUC (already BE in the first stage) no regulator would accept that. Once you dosed subjects, you have to use the data. No way out.

Dif-tor heh smusma 🖖
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
21,206 posts in 4,425 threads, 1,481 registered users;
online 5 (0 registered, 5 guests [including 4 identified bots]).
Forum time: Tuesday 19:34 CET (Europe/Vienna)

All we know about the world teaches us that the effects of A and B
are always different—in some decimal place—for any A and B.
Thus asking “are the effects different?” is foolish.    John W. Tukey

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz